0000001800FALSENew York Stock ExchangeChicago Stock Exchange, Inc.00000018002024-07-182024-07-180000001800exch:XNYS2024-07-182024-07-180000001800exch:XCHI2024-07-182024-07-18
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D. C. 20549
_______________________________________________________
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
July 18, 2024
Date of Report (Date of earliest event reported)
ABBOTT LABORATORIES
(Exact name of registrant as specified in charter)
_______________________________________________________
| | | | | | | | | | | | | | |
| Illinois | | 1-2189 | | 36-0698440 |
(State or other Jurisdiction
of Incorporation) | | (Commission File Number) | | (IRS Employer
Identification No.) |
_______________________________________________________
100 Abbott Park Road
Abbott Park, Illinois 60064-6400
(Address of principal executive offices)(Zip Code)
Registrant’s telephone number, including area code: (224) 667-6100
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| | | | | |
| o | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| o | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| o | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| o | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities Registered Pursuant to Section 12(b) of the Act:
| | | | | | | | |
| Title of Each Class | Trading Symbol(s) | Name of Each Exchange on Which Registered |
| Common Shares, Without Par Value | ABT | New York Stock Exchange Chicago Stock Exchange, Inc. |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company o
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
Item 2.02 Results of Operations and Financial Condition
On July 18, 2024, Abbott Laboratories announced its results of operations for the second quarter 2024.
Furnished as Exhibit 99.1, and incorporated herein by reference, is the news release issued by Abbott announcing those results. In that news release, Abbott uses various non-GAAP financial measures including, among others, net earnings excluding specified items. These non-GAAP financial measures adjust for factors that are unusual or unpredictable, such as expenses primarily associated with acquisitions, a divestiture, restructuring actions, cost reduction initiatives, fair value adjustments to the contingent consideration related to business acquisitions, impairment charges related to intangible assets or equity investments, certain regulatory costs, tax benefits associated with specified items, net tax expense as a result of the resolution of various tax positions related to prior years, and excess tax benefits associated with share-based compensation. These non-GAAP financial measures also exclude intangible amortization expense to provide greater visibility on the results of operations excluding these costs, similar to how Abbott’s management internally assesses performance. Abbott’s management believes the presentation of these non-GAAP financial measures provides useful information to investors regarding Abbott’s results of operations as these non-GAAP financial measures allow investors to better evaluate ongoing business performance. Abbott’s management also uses these non-GAAP financial measures internally to monitor performance of the businesses. Abbott, however, cautions investors to consider these non-GAAP financial measures in addition to, and not as a substitute for, financial measures prepared in accordance with GAAP.
Item 9.01 Financial Statements and Exhibits
| | | | | | | | |
| Exhibit No. | | Exhibit |
| | |
| | |
| | |
| 104 | | Cover Page Interactive Data File (the cover page XBRL tags are embedded in the Inline XBRL document). |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| | | | | | | | |
| ABBOTT LABORATORIES |
| |
| Date: July 18, 2024 | By: | /s/ Philip P. Boudreau |
| | Philip P. Boudreau |
| | Executive Vice President, Finance and Chief Financial Officer |
Exhibit 99.1 9.1
Abbott Reports Second-Quarter 2024 Results and Raises
Full-Year Guidance
–Sales of $10.4 billion driven by strong underlying base business performance
–Reported sales growth of 4.0 percent; organic sales growth for underlying base business of 9.3 percent1, led by double-digit growth in Medical Devices
–Continues to strengthen portfolio with new product approvals
ABBOTT PARK, Ill., July 18, 2024 — Abbott today announced financial results for the second quarter ended June 30, 2024.
•Second-quarter GAAP diluted EPS of $0.74 and adjusted diluted EPS of $1.14, which excludes specified items.
•Abbott raised its full-year 2024 EPS guidance range. Abbott projects full-year diluted EPS on a GAAP basis of $3.30 to $3.40 and projects adjusted diluted EPS of $4.61 to $4.71.
•Abbott narrowed its full-year 2024 organic sales growth guidance range, excluding COVID-19 testing-related sales, to 9.5% to 10.0%, which represents an increase at the midpoint of the range2.
•In April, Abbott announced U.S. Food and Drug Administration (FDA) approval of the Esprit™ below-the-knee (BTK) system, a breakthrough innovation for people living with peripheral artery disease. This system is designed to keep arteries open and deliver a drug to support vessel healing prior to completely dissolving.
•In June, Abbott announced U.S. FDA clearance for two new over-the-counter continuous glucose monitoring systems — Lingo™ and Libre Rio™, which are based on Abbott's world-leading FreeStyle Libre® continuous glucose monitoring technology3.
•In June, Abbott obtained CE Mark for its AVEIR® dual chamber (DR) leadless pacemaker system, the world's first dual chamber leadless pacemaker system that treats people with abnormal or slow heart rhythms.
•During the first half of 2024, Abbott announced 10 new growth opportunities coming from the company's highly productive R&D pipeline. These include a combination of new product approvals and new treatment indications.
"We achieved another quarter of strong growth in our underlying base business," said Robert B. Ford, chairman and chief executive officer, Abbott. "We have a lot of positive momentum heading into the second half of the year and are raising our full-year guidance."
SECOND-QUARTER BUSINESS OVERVIEW
Management believes that measuring sales growth rates on an organic basis, which excludes the impact of foreign exchange, the impact of discontinuing the ZonePerfect® product line in the Nutrition business, and the impact of the acquisition of Cardiovascular Systems, Inc. (CSI) during the first year post-acquisition, is an appropriate way for investors to best understand the core underlying performance of the business. Management further believes that measuring sales growth rates on an organic basis excluding COVID-19 tests is an appropriate way for investors to best understand underlying base business performance as the COVID-19 pandemic has shifted to an endemic state, resulting in significantly lower demand for COVID-19 tests.
Note: In order to compute results excluding the impact of exchange rates, current year U.S. dollar sales are multiplied or divided, as appropriate, by the current year average foreign exchange rates and then those amounts are multiplied or divided, as appropriate, by the prior year average foreign exchange rates.
Second Quarter 2024 Results (2Q24)
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Sales 2Q24 ($ in millions) | Total Company | | Nutrition | | Diagnostics | | Established Pharmaceuticals | | Medical Devices |
| U.S. | 3,934 | | | 933 | | | 812 | | | — | | | 2,185 | |
| International | 6,443 | | | 1,217 | | | 1,383 | | | 1,294 | | | 2,549 | |
| Total reported | 10,377 | | | 2,150 | | | 2,195 | | | 1,294 | | | 4,734 | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| % Change vs. 2Q23 | | | | | | | | | |
| U.S. | 4.7 | | | 6.0 | | | (15.5) | | | n/a | | 14.2 | |
| International | 3.6 | | | 1.7 | | | 1.9 | | | 0.6 | | | 7.0 | |
| Total reported | 4.0 | | | 3.5 | | | (5.3) | | | 0.6 | | | 10.2 | |
| Impact of foreign exchange | (3.5) | | | (3.6) | | | (3.8) | | | (7.5) | | | (2.2) | |
Impact of business exit and acquisition* | 0.1 | | | (0.4) | | | — | | | — | | | 0.3 | |
| Organic | 7.4 | | | 7.5 | | | (1.5) | | | 8.1 | | | 12.1 | |
Impact of COVID-19 testing sales (4) | (1.9) | | | — | | | (7.4) | | | — | | | — | |
| Organic (excluding COVID-19 tests) | 9.3 | | | 7.5 | | | 5.9 | | | 8.1 | | | 12.1 | |
| | | | | | | | | |
| U.S. | 9.0 | | | 6.9 | | | (0.3) | | | n/a | | 13.5 | |
| International | 9.4 | | | 7.9 | | | 9.5 | | | 8.1 | | | 10.9 | |
First Half 2024 Results (1H24)
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Sales 1H24 ($ in millions) | Total Company | | Nutrition | | Diagnostics | | Established Pharmaceuticals | | Medical Devices |
| U.S. | 7,780 | | | 1,811 | | | 1,743 | | | — | | | 4,219 | |
| International | 12,561 | | | 2,407 | | | 2,666 | | | 2,520 | | | 4,968 | |
| Total reported | 20,341 | | | 4,218 | | | 4,409 | | | 2,520 | | | 9,187 | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| % Change vs. 1H23 | | | | | | | | | |
| U.S. | 1.2 | | | 7.0 | | | (24.1) | | | n/a | | 14.3 | |
| International | 4.3 | | | 2.4 | | | (1.6) | | | 1.8 | | | 10.3 | |
| Total reported | 3.1 | | | 4.3 | | | (11.9) | | | 1.8 | | | 12.1 | |
| Impact of foreign exchange | (3.2) | | | (3.1) | | | (2.9) | | | (9.0) | | | (1.7) | |
Impact of business exit and acquisition* | 0.2 | | | (0.2) | | | — | | | — | | | 0.7 | |
| Organic | 6.1 | | | 7.6 | | | (9.0) | | | 10.8 | | | 13.1 | |
Impact of COVID-19 testing sales (4) | (3.9) | | | — | | | (14.7) | | | — | | | — | |
| Organic (excluding COVID-19 tests) | 10.0 | | | 7.6 | | | 5.7 | | | 10.8 | | | 13.1 | |
| | | | | | | | | |
| U.S. | 9.5 | | | 7.5 | | | 3.3 | | | n/a | | 12.8 | |
| International | 10.3 | | | 7.7 | | | 7.1 | | | 10.8 | | | 13.4 | |
Refer to page 16 for a reconciliation of adjusted historical revenue to reported revenue.
*Reflects the impact of discontinuing the ZonePerfect® product line in the Nutrition business in March 2024 and the acquisition of CSI on April 27, 2023. Organic sales growth excludes the impact of the acquired business from January through April 2024.
Nutrition
Second Quarter 2024 Results (2Q24)
| | | | | | | | | | | | | | | | | |
Sales 2Q24 ($ in millions) | Total | | Pediatric | | Adult |
| U.S. | 933 | | | 564 | | | 369 | |
| International | 1,217 | | | 495 | | | 722 | |
| Total reported | 2,150 | | | 1,059 | | | 1,091 | |
| | | | | | | | | | | | | | | | | |
| % Change vs. 2Q23 | | | | | |
| U.S. | 6.0 | | | 11.3 | | | (1.2) | |
| International | 1.7 | | | (4.4) | | | 6.4 | |
| Total reported | 3.5 | | | 3.4 | | | 3.7 | |
| Impact of foreign exchange | (3.6) | | | (1.6) | | | (5.4) | |
Impact of business exit* | (0.4) | | | — | | | (0.8) | |
| Organic | 7.5 | | | 5.0 | | | 9.9 | |
| | | | | |
| U.S. | 6.9 | | | 11.3 | | | 0.8 | |
| International | 7.9 | | | (1.0) | | | 14.7 | |
Worldwide Nutrition sales increased 3.5 percent on a reported basis and 7.5 percent on an organic basis in the second quarter.
In Pediatric Nutrition, global sales increased 3.4 percent on a reported basis and 5.0 percent on an organic basis. Sales in the U.S. reflect continued market share gains in the infant formula business.
In Adult Nutrition, global sales increased 3.7 percent on a reported basis and 9.9 percent on an organic basis, which was led by strong growth of Ensure®, Abbott's market-leading complete and balanced nutrition brand.
First Half 2024 Results (1H24)
| | | | | | | | | | | | | | | | | |
Sales 1H24 ($ in millions) | Total | | Pediatric | | Adult |
| U.S. | 1,811 | | | 1,078 | | | 733 | |
| International | 2,407 | | | 990 | | | 1,417 | |
| Total reported | 4,218 | | | 2,068 | | | 2,150 | |
| | | | | | | | | | | | | | | | | |
| % Change vs. 1H23 | | | | | |
| U.S. | 7.0 | | | 11.6 | | | 0.8 | |
| International | 2.4 | | | 0.7 | | | 3.6 | |
| Total reported | 4.3 | | | 6.1 | | | 2.6 | |
| Impact of foreign exchange | (3.1) | | | (1.5) | | | (4.6) | |
| Impact of business exit* | (0.2) | | | — | | | (0.4) | |
| Organic | 7.6 | | | 7.6 | | | 7.6 | |
| | | | | |
| U.S. | 7.5 | | | 11.6 | | | 1.9 | |
| International | 7.7 | | | 3.7 | | | 10.5 | |
*Reflects the impact of discontinuing the ZonePerfect® product line. This action was initiated in March 2024.
Diagnostics
Second Quarter 2024 Results (2Q24)
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Sales 2Q24 ($ in millions) | Total | | Core Laboratory | | Molecular | | Point of Care | | Rapid Diagnostics |
| U.S. | 812 | | | 327 | | | 33 | | | 107 | | | 345 | |
| International | 1,383 | | | 1,002 | | | 94 | | | 49 | | | 238 | |
| Total reported | 2,195 | | | 1,329 | | | 127 | | | 156 | | | 583 | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| % Change vs. 2Q23 | | | | | | | | | |
| U.S. | (15.5) | | | 5.1 | | | (22.5) | | | 8.1 | | | (32.1) | |
| International | 1.9 | | | 2.1 | | | (4.9) | | | 14.1 | | | 2.1 | |
| Total reported | (5.3) | | | 2.8 | | | (10.3) | | | 9.9 | | | (21.3) | |
| Impact of foreign exchange | (3.8) | | | (5.8) | | | (0.9) | | | (0.1) | | | (1.5) | |
| Organic | (1.5) | | | 8.6 | | | (9.4) | | | 10.0 | | | (19.8) | |
Impact of COVID-19 testing sales (4) | (7.4) | | | (0.2) | | | (3.8) | | | — | | | (20.2) | |
| Organic (excluding COVID-19 tests) | 5.9 | | | 8.8 | | | (5.6) | | | 10.0 | | | 0.4 | |
| | | | | | | | | |
| U.S. | (0.3) | | | 5.3 | | | (19.0) | | | 8.1 | | | (6.6) | |
| International | 9.5 | | | 9.9 | | | — | | | 14.5 | | | 11.0 | |
As expected, Diagnostics sales growth in the second quarter was negatively impacted by year-over-year declines in COVID-19 testing-related sales4. Worldwide COVID-19 testing sales were $102 million in the second quarter of 2024 compared to $263 million in the second quarter of the prior year.
Excluding COVID-19 testing-related sales, global Diagnostics sales increased 1.8 percent on a reported basis and 5.9 percent on an organic basis.
Excluding COVID-19 testing-related sales, global Core Laboratory Diagnostics sales increased 3.0 percent on a reported basis and 8.8 percent on an organic basis, led by continued strong adoption of Abbott's Alinity® family of diagnostics systems and testing portfolios.
First Half 2024 Results (1H24)
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Sales 1H24 ($ in millions) | Total | | Core Laboratory | | Molecular | | Point of Care | | Rapid Diagnostics |
| U.S. | 1,743 | | | 637 | | | 75 | | | 205 | | | 826 | |
| International | 2,666 | | | 1,897 | | | 181 | | | 90 | | | 498 | |
| Total reported | 4,409 | | | 2,534 | | | 256 | | | 295 | | | 1,324 | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| % Change vs. 1H23 | | | | | | | | | |
| U.S. | (24.1) | | | 6.2 | | | (16.3) | | | 6.9 | | | (41.6) | |
| International | (1.6) | | | 1.2 | | | (8.8) | | | 6.9 | | | (9.7) | |
| Total reported | (11.9) | | | 2.4 | | | (11.1) | | | 6.9 | | | (32.7) | |
| Impact of foreign exchange | (2.9) | | | (4.9) | | | (0.6) | | | — | | | (1.1) | |
| Organic | (9.0) | | | 7.3 | | | (10.5) | | | 6.9 | | | (31.6) | |
Impact of COVID-19 testing sales (4) | (14.7) | | | (0.3) | | | (7.3) | | | — | | | (34.6) | |
| Organic (excluding COVID-19 tests) | 5.7 | | | 7.6 | | | (3.2) | | | 6.9 | | | 3.0 | |
| | | | | | | | | |
| U.S. | 3.3 | | | 6.5 | | | (6.7) | | | 6.9 | | | 0.3 | |
| International | 7.1 | | | 7.9 | | | (1.8) | | | 7.1 | | | 7.1 | |
Established Pharmaceuticals
Second Quarter 2024 Results (2Q24)
| | | | | | | | | | | | | | | | | |
Sales 2Q24 ($ in millions) | Total | | Key Emerging Markets | | Other |
| U.S. | — | | | — | | | — | |
| International | 1,294 | | | 988 | | | 306 | |
| Total reported | 1,294 | | | 988 | | | 306 | |
| | | | | | | | | | | | | | | | | |
| % Change vs. 2Q23 | | | | | |
| U.S. | n/a | | n/a | | n/a |
| International | 0.6 | | | (0.2) | | | 3.1 | |
| Total reported | 0.6 | | | (0.2) | | | 3.1 | |
| Impact of foreign exchange | (7.5) | | | (9.0) | | | (2.6) | |
| Organic | 8.1 | | | 8.8 | | | 5.7 | |
| | | | | |
| U.S. | n/a | | n/a | | n/a |
| International | 8.1 | | | 8.8 | | | 5.7 | |
Established Pharmaceuticals sales increased 0.6 percent on a reported basis and 8.1 percent on an organic basis in the second quarter.
Key Emerging Markets include several emerging countries that represent the most attractive long-term growth opportunities for Abbott's branded generics product portfolio. Sales in these geographies decreased 0.2 percent on a reported basis and increased 8.8 percent on an organic basis, led by growth in several geographies and therapeutic areas, including cardiometabolic, gastroenterology, and central nervous system/pain management.
First Half 2024 Results (1H24)
| | | | | | | | | | | | | | | | | |
Sales 1H24 ($ in millions) | Total | | Key Emerging Markets | | Other |
| U.S. | — | | | — | | | — | |
| International | 2,520 | | | 1,916 | | | 604 | |
| Total reported | 2,520 | | | 1,916 | | | 604 | |
| | | | | | | | | | | | | | | | | |
| % Change vs. 1H23 | | | | | |
| U.S. | n/a | | n/a | | n/a |
| International | 1.8 | | | 0.7 | | | 5.3 | |
| Total reported | 1.8 | | | 0.7 | | | 5.3 | |
| Impact of foreign exchange | (9.0) | | | (11.3) | | | (1.6) | |
| Organic | 10.8 | | | 12.0 | | | 6.9 | |
| | | | | |
| U.S. | n/a | | n/a | | n/a |
| International | 10.8 | | | 12.0 | | | 6.9 | |
Medical Devices
Second Quarter 2024 Results (2Q24)
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Sales 2Q24 ($ in millions) | Total | | Rhythm Management | | Electro-
physiology | | Heart Failure | | Vascular | | Structural Heart | | Neuro-modulation | | Diabetes Care |
| U.S. | 2,185 | | | 292 | | | 287 | | | 244 | | | 275 | | | 258 | | | 192 | | | 637 | |
| International | 2,549 | | | 315 | | | 340 | | | 77 | | | 449 | | | 306 | | | 51 | | | 1,011 | |
| Total reported | 4,734 | | | 607 | | | 627 | | | 321 | | | 724 | | | 564 | | | 243 | | | 1,648 | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| % Change vs. 2Q23 | | | | | | | | | | | | | | | |
| U.S. | 14.2 | | | 8.5 | | | 16.8 | | | 7.7 | | | 4.3 | | | 17.9 | | | 3.7 | | | 26.3 | |
| International | 7.0 | | | 0.4 | | | 10.5 | | | 11.4 | | | (0.4) | | | 9.4 | | | 21.7 | | | 10.0 | |
| Total reported | 10.2 | | | 4.2 | | | 13.3 | | | 8.6 | | | 1.3 | | | 13.2 | | | 7.0 | | | 15.8 | |
| Impact of foreign exchange | (2.2) | | | (1.7) | | | (3.4) | | | (0.3) | | | (2.0) | | | (2.4) | | | (1.2) | | | (2.4) | |
| Impact of acquisition* | 0.3 | | | — | | | — | | | — | | | 2.1 | | | — | | | — | | | — | |
| Organic | 12.1 | | | 5.9 | | | 16.7 | | | 8.9 | | | 1.2 | | | 15.6 | | | 8.2 | | | 18.2 | |
| | | | | | | | | | | | | | | |
| U.S. | 13.5 | | | 8.5 | | | 16.8 | | | 7.7 | | | (0.8) | | | 17.9 | | | 3.7 | | | 26.3 | |
| International | 10.9 | | | 3.7 | | | 16.7 | | | 12.8 | | | 2.5 | | | 13.8 | | | 28.4 | | | 13.7 | |
Worldwide Medical Devices sales increased 10.2 percent on a reported basis and 12.1 percent on an organic basis in the second quarter, including double-digit organic growth in both the U.S. and internationally.
Sales growth was led by double-digit growth in Diabetes Care, Electrophysiology, and Structural Heart. Several recently launched products and new indications contributed to the strong performance, including Amplatzer® Amulet®, Navitor®, TriClip®, and AVEIR®.
In Electrophysiology, sales grew 13.3 percent on a reported basis and 16.7 percent on an organic basis, which included double-digit growth in catheters and cardiac mapping-related products, and double-digit growth in all major geographic regions.
In Diabetes Care, FreeStyle Libre sales were $1.6 billion, which represents sales growth of 18.4 percent on a reported basis and 20.4 percent on an organic basis.
First Half 2024 Results (1H24)
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Sales 1H24 ($ in millions) | Total | | Rhythm Management | | Electro-
physiology | | Heart Failure | | Vascular | | Structural Heart | | Neuro-modulation | | Diabetes Care |
| U.S. | 4,219 | | | 563 | | | 556 | | | 481 | | | 529 | | | 491 | | | 373 | | | 1,226 | |
| International | 4,968 | | | 606 | | | 658 | | | 145 | | | 884 | | | 588 | | | 96 | | | 1,991 | |
| Total reported | 9,187 | | | 1,169 | | | 1,214 | | | 626 | | | 1,413 | | | 1,079 | | | 469 | | | 3,217 | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| % Change vs. 1H23 | | | | | | | | | | | | | | | |
| U.S. | 14.3 | | | 6.6 | | | 15.0 | | | 8.2 | | | 9.8 | | | 14.4 | | | 9.6 | | | 24.6 | |
| International | 10.3 | | | 4.4 | | | 14.4 | | | 9.7 | | | 4.1 | | | 10.9 | | | 15.9 | | | 13.6 | |
| Total reported | 12.1 | | | 5.4 | | | 14.7 | | | 8.6 | | | 6.1 | | | 12.5 | | | 10.9 | | | 17.6 | |
| Impact of foreign exchange | (1.7) | | | (1.3) | | | (2.8) | | | (0.1) | | | (1.5) | | | (1.8) | | | (1.6) | | | (1.8) | |
| Impact of acquisition* | 0.7 | | | — | | | — | | | — | | | 4.3 | | | — | | | — | | | — | |
| Organic | 13.1 | | | 6.7 | | | 17.5 | | | 8.7 | | | 3.3 | | | 14.3 | | | 12.5 | | | 19.4 | |
| | | | | | | | | | | | | | | |
| U.S. | 12.8 | | | 6.6 | | | 15.0 | | | 8.2 | | | (1.3) | | | 14.4 | | | 9.6 | | | 24.6 | |
| International | 13.4 | | | 6.8 | | | 19.6 | | | 10.1 | | | 6.0 | | | 14.3 | | | 24.1 | | | 16.5 | |
*Abbott completed the acquisition of CSI on April 27, 2023. For purposes of calculating organic sales growth, the impact from this acquired business has been excluded from January through April 2024.
ABBOTT'S EARNINGS-PER-SHARE GUIDANCE
Abbott projects full-year 2024 diluted earnings per share under GAAP of $3.30 to $3.40. Abbott forecasts specified items for the full-year 2024 of $1.31 per share primarily related to intangible amortization, restructuring and cost reduction initiatives and other net expenses. Excluding specified items, projected adjusted diluted earnings per share would be $4.61 to $4.71 for the full-year 2024.
Abbott projects third-quarter 2024 diluted earnings per share under GAAP of $0.85 to $0.89. Abbott forecasts specified items for the third-quarter 2024 of $0.33 per share primarily related to intangible amortization, restructuring and cost reduction initiatives and other net expenses. Excluding specified items, projected adjusted diluted earnings per share would be $1.18 to $1.22 for the third quarter 2024.
ABBOTT DECLARES 402ND CONSECUTIVE QUARTERLY DIVIDEND
On June 14, 2024, the board of directors of Abbott declared the company's quarterly dividend of $0.55 per share. Abbott's cash dividend is payable Aug. 15, 2024, to shareholders of record at the close of business on July 15, 2024.
Abbott has increased its dividend payout for 52 consecutive years and is a member of the S&P 500 Dividend Aristocrats Index, which tracks companies that have annually increased their dividend for at least 25 consecutive years.
About Abbott:
Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. Our 114,000 colleagues serve people in more than 160 countries.
Connect with us at www.abbott.com and on LinkedIn, Facebook, Instagram, X and YouTube.
Abbott will live-webcast its second-quarter earnings conference call through its Investor Relations website at www.abbottinvestor.com at 8 a.m. Central time today. An archived edition of the webcast will be available later in the day.
— Private Securities Litigation Reform Act of 1995 —
A Caution Concerning Forward-Looking Statements
Some statements in this news release may be forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. Abbott cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Economic, competitive, governmental, technological and other factors that may affect Abbott's operations are discussed in Item 1A, "Risk Factors" in our Annual Report on Form 10-K for the year ended Dec. 31, 2023, and are incorporated herein by reference. Abbott undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.
| | | | | |
Abbott Financial: Michael Comilla, 224-668-1872 Tamika LeBean, 224-399-5082 Ryan Aliff, 224-667-2299 | Abbott Media: Karen Twigg May, 224-668-2681 Kate Dyer, 224-668-9965 |
1In the second quarter of 2024, total worldwide sales were $10.377 billion and COVID-19 testing-related sales were $102 million. In the second quarter of 2023, total worldwide sales were $9.978 billion and COVID-19 testing-related sales were $263 million.
2Abbott has not provided the related GAAP financial measure for organic sales growth, excluding COVID-19 testing-related sales, on a forward-looking basis because the company is unable to predict with reasonable certainty the impact of foreign exchange due to the unpredictability of future changes in foreign exchange rates, which could significantly impact reported sales growth. In addition, as the COVID-19 pandemic has shifted to an endemic state, the company has determined that it is unable to predict with reasonable certainty future COVID-19 test sales due to the unpredictability of demand for COVID-19 tests.
3Data on file. Abbott Diabetes Care.
4Diagnostic sales and COVID-19 testing-related sales in 2024 and 2023 are summarized below:
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Sales 2Q24 | | | | COVID Tests Sales 2Q24 |
| ($ in millions) | U.S. | | Int'l | | Total | | | | | | | | U.S. | | Int'l | | Total |
| Total Diagnostics | 812 | | | 1,383 | | | 2,195 | | | | | | | | | 69 | | | 33 | | | 102 | |
| Core Laboratory | 327 | | | 1,002 | | | 1,329 | | | | | | | | | 1 | | | 1 | | | 2 | |
| Molecular | 33 | | | 94 | | | 127 | | | | | | | | | 2 | | | 1 | | | 3 | |
| | | | | | | | | | | | | | | | | |
| Rapid Diagnostics | 345 | | | 238 | | | 583 | | | | | | | | | 66 | | | 31 | | | 97 | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Sales 2Q23 | | | | COVID Tests Sales 2Q23 |
| ($ in millions) | U.S. | | Int'l | | Total | | | | | | | | U.S. | | Int'l | | Total |
| Total Diagnostics | 961 | | | 1,356 | | | 2,317 | | | | | | | | | 216 | | | 47 | | | 263 | |
| Core Laboratory | 311 | | | 982 | | | 1,293 | | | | | | | | | 2 | | | 3 | | | 5 | |
| Molecular | 43 | | | 98 | | | 141 | | | | | | | | | 4 | | | 4 | | | 8 | |
| | | | | | | | | | | | | | | | | |
| Rapid Diagnostics | 508 | | | 233 | | | 741 | | | | | | | | | 210 | | | 40 | | | 250 | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Sales 1H24 | | | | COVID Tests Sales 1H24 |
| ($ in millions) | U.S. | | Int'l | | Total | | | | | | | | U.S. | | Int'l | | Total |
| Total Diagnostics | 1,743 | | | 2,666 | | | 4,409 | | | | | | | | | 222 | | | 84 | | | 306 | |
| Core Laboratory | 637 | | | 1,897 | | | 2,534 | | | | | | | | | 2 | | | 3 | | | 5 | |
| Molecular | 75 | | | 181 | | | 256 | | | | | | | | | 5 | | | 2 | | | 7 | |
| | | | | | | | | | | | | | | | | |
| Rapid Diagnostics | 826 | | | 498 | | | 1,324 | | | | | | | | | 215 | | | 79 | | | 294 | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Sales 1H23 | | | | COVID Tests Sales 1H23 |
| ($ in millions) | U.S. | | Int'l | | Total | | | | | | | | U.S. | | Int'l | | Total |
| Total Diagnostics | 2,296 | | | 2,709 | | | 5,005 | | | | | | | | | 824 | | | 169 | | | 993 | |
| Core Laboratory | 600 | | | 1,875 | | | 2,475 | | | | | | | | | 4 | | | 7 | | | 11 | |
| Molecular | 90 | | | 198 | | | 288 | | | | | | | | | 14 | | | 14 | | | 28 | |
| | | | | | | | | | | | | | | | | |
| Rapid Diagnostics | 1,414 | | | 552 | | | 1,966 | | | | | | | | | 806 | | | 148 | | | 954 | |
Abbott Laboratories and Subsidiaries
Condensed Consolidated Statement of Earnings
Second Quarter Ended June 30, 2024 and 2023
(in millions, except per share data)
(unaudited)
| | | | | | | | | | | | | | | | | | | | |
| 2Q24 | | 2Q23 | | % Change | |
| Net Sales | $10,377 | | $9,978 | | 4.0 | | |
| | | | | | |
| Cost of products sold, excluding amortization expense | 4,603 | | | 4,483 | | | 2.7 | | |
| Amortization of intangible assets | 471 | | | 498 | | | (5.6) | | |
| Research and development | 698 | | | 715 | | | (2.3) | | |
| Selling, general, and administrative | 2,936 | | | 2,740 | | | 7.1 | | |
| Total Operating Cost and Expenses | 8,708 | | | 8,436 | | | 3.2 | | |
| | | | | | |
| Operating Earnings | 1,669 | | | 1,542 | | | 8.2 | | |
| | | | | | |
| Interest expense, net | 58 | | | 61 | | | (5.1) | | |
| Net foreign exchange (gain) loss | (6) | | | 21 | | | n/m | |
| Other (income) expense, net | 10 | | | (176) | | | n/m | |
| Earnings before taxes | 1,607 | | | 1,636 | | | (1.8) | | |
| Taxes on earnings | 305 | | | 261 | | | 17.1 | | 1) |
| | | | | | |
| Net Earnings | $1,302 | | $1,375 | | (5.3) | | |
| | | | | | |
| Net Earnings excluding Specified Items, as described below | $2,003 | | $1,893 | | 5.8 | | 2) |
| | | | | | |
| Diluted Earnings per Common Share | $0.74 | | $0.78 | | (5.1) | | |
| | | | | | |
| Diluted Earnings per Common Share, excluding Specified Items, as described below | $1.14 | | $1.08 | | 5.6 | | 2) |
| | | | | | |
| Average Number of Common Shares Outstanding Plus Dilutive Common Stock Options | 1,751 | | | 1,750 | | | | |
NOTES:
See tables on page 13 for an explanation of certain non-GAAP financial information.
n/m = Percent change is not meaningful.
See footnotes on the following page.
1)2024 Taxes on Earnings includes the recognition of approximately $25 million of net tax expense as a result of the resolution of various tax positions related to prior years.
2023 Taxes on Earnings includes the recognition of approximately $40 million of net tax expense as a result of the resolution of various tax positions related to prior years.
2)2024 Net Earnings and Diluted Earnings per Common Share, excluding Specified Items, excludes net after-tax charges of $701 million, or $0.40 per share, for intangible amortization, charges related to restructuring and cost reduction initiatives, expenses associated with acquisitions and a divestiture, and other net expenses.
2023 Net Earnings and Diluted Earnings per Common Share, excluding Specified Items, excludes net after-tax charges of $518 million, or $0.30 per share, for intangible amortization, charges related to restructuring and cost reduction initiatives, expenses associated with acquisitions and other net expenses.
Abbott Laboratories and Subsidiaries
Condensed Consolidated Statement of Earnings
First Half Ended June 30, 2024 and 2023
(in millions, except per share data)
(unaudited)
| | | | | | | | | | | | | | | | | | | | |
| 1H24 | | 1H23 | | % Change | |
| Net Sales | $20,341 | | $19,725 | | 3.1 | | |
| | | | | | |
| Cost of products sold, excluding amortization expense | 9,066 | | | 8,814 | | | 2.9 | | |
| Amortization of intangible assets | 943 | | | 989 | | | (4.7) | | |
| Research and development | 1,382 | | | 1,369 | | | 0.9 | | |
| Selling, general, and administrative | 5,895 | | | 5,502 | | | 7.1 | | |
| Total Operating Cost and Expenses | 17,286 | | | 16,674 | | | 3.7 | | |
| | | | | | |
| Operating Earnings | 3,055 | | | 3,051 | | | 0.2 | | |
| | | | | | |
| Interest expense, net | 119 | | | 113 | | | 5.6 | | |
| Net foreign exchange (gain) loss | (6) | | | 27 | | | n/m | |
| Other (income) expense, net | (101) | | | (287) | | | n/m | |
| Earnings before taxes | 3,043 | | | 3,198 | | | (4.8) | | |
| Taxes on earnings | 516 | | | 505 | | | 2.2 | | 1) |
| | | | | | |
| Net Earnings | $2,527 | | $2,693 | | (6.2) | | |
| | | | | | |
| Net Earnings excluding Specified Items, as described below | $3,732 | | $3,708 | | 0.7 | | 2) |
| | | | | | |
| Diluted Earnings per Common Share | $1.44 | | $1.53 | | (5.9) | | |
| | | | | | |
| Diluted Earnings per Common Share, excluding Specified Items, as described below | $2.12 | | $2.11 | | 0.5 | | 2) |
| | | | | | |
| Average Number of Common Shares Outstanding Plus Dilutive Common Stock Options | 1,750 | | | 1,751 | | | | |
NOTES:
See tables on page 14 for an explanation of certain non-GAAP financial information.
n/m = Percent change is not meaningful.
See footnotes on the following page.
1)2024 Taxes on Earnings includes the recognition of approximately $35 million of net tax expense as a result of the resolution of various tax positions related to prior years.
2023 Taxes on Earnings includes the recognition of approximately $62 million of net tax expense as a result of the resolution of various tax positions related to prior years.
2)2024 Net Earnings and Diluted Earnings per Common Share, excluding Specified Items, excludes net after-tax charges of $1.205 billion, or $0.68 per share, for intangible amortization, charges related to restructuring and cost reduction initiatives, expenses associated with acquisitions and a divestiture, and other net expenses.
2023 Net Earnings and Diluted Earnings per Common Share, excluding Specified Items, excludes net after-tax charges of $1.015 billion, or $0.58 per share, for intangible amortization, charges related to restructuring and cost reduction initiatives, expenses associated with acquisitions and other net expenses.
Abbott Laboratories and Subsidiaries
Non-GAAP Reconciliation of Financial Information
Second Quarter Ended June 30, 2024 and 2023
(in millions, except per share data)
(unaudited)
| | | | | | | | | | | | | | | | | | | |
| 2Q24 |
| As
Reported (GAAP) | | Specified Items | | As
Adjusted | | |
| | | | | | | |
Intangible Amortization | $ | 471 | | | $ | (471) | | | $ | — | | | |
Gross Margin | 5,303 | | | 506 | | | 5,809 | | | |
R&D | 698 | | | (41) | | | 657 | | | |
SG&A | 2,936 | | | (57) | | | 2,879 | | | |
Other (income) expense, net | 10 | | | (145) | | | (135) | | | |
Earnings before taxes | 1,607 | | | 749 | | | 2,356 | | | |
Taxes on Earnings | 305 | | | 48 | | | 353 | | | |
Net Earnings | 1,302 | | | 701 | | | 2,003 | | | |
Diluted Earnings per Share | $ | 0.74 | | | $ | 0.40 | | | $ | 1.14 | | | |
Specified items reflect intangible amortization expense of $471 million and other net expenses of $278 million associated with restructuring actions, acquisitions, a divestiture and other net expenses. See page 17 for additional details regarding specified items.
| | | | | | | | | | | | | | | | | | | |
| 2Q23 |
| As
Reported (GAAP) | | Specified Items | | As
Adjusted | | |
| | | | | | | |
Intangible Amortization | $ | 498 | | | $ | (498) | | | $ | — | | | |
Gross Margin | 4,997 | | | 529 | | | 5,526 | | | |
R&D | 715 | | | (72) | | | 643 | | | |
SG&A | 2,740 | | | (22) | | | 2,718 | | | |
Other (income) expense, net | (176) | | | 57 | | | (119) | | | |
Earnings before taxes | 1,636 | | | 566 | | | 2,202 | | | |
Taxes on Earnings | 261 | | | 48 | | | 309 | | | |
Net Earnings | 1,375 | | | 518 | | | 1,893 | | | |
Diluted Earnings per Share | $ | 0.78 | | | $ | 0.30 | | | $ | 1.08 | | | |
Specified items reflect intangible amortization expense of $498 million and other net expenses of $68 million associated with restructuring actions, costs associated with acquisitions and other net expenses. See page 18 for additional details regarding specified items.
Abbott Laboratories and Subsidiaries
Non-GAAP Reconciliation of Financial Information
First Half Ended June 30, 2024 and 2023
(in millions, except per share data)
(unaudited)
| | | | | | | | | | | | | | | | | | | |
| 1H24 |
| As
Reported (GAAP) | | Specified Items | | As
Adjusted | | |
| | | | | | | |
Intangible Amortization | $ | 943 | | | $ | (943) | | | $ | — | | | |
Gross Margin | 10,332 | | | 1,024 | | | 11,356 | | | |
R&D | 1,382 | | | (62) | | | 1,320 | | | |
SG&A | 5,895 | | | (91) | | | 5,804 | | | |
Other (income) expense, net | (101) | | | (171) | | | (272) | | | |
Earnings before taxes | 3,043 | | | 1,348 | | | 4,391 | | | |
Taxes on Earnings | 516 | | | 143 | | | 659 | | | |
Net Earnings | 2,527 | | | 1,205 | | | 3,732 | | | |
Diluted Earnings per Share | $ | 1.44 | | | $ | 0.68 | | | $ | 2.12 | | | |
Specified items reflect intangible amortization expense of $943 million and other net expenses of $405 million associated with restructuring actions, acquisitions, a divestiture and other net expenses. See page 19 for additional details regarding specified items.
| | | | | | | | | | | | | | | | | | | |
| 1H23 |
| As
Reported (GAAP) | | Specified Items | | As
Adjusted | | |
| | | | | | | |
Intangible Amortization | $ | 989 | | | $ | (989) | | | $ | — | | | |
Gross Margin | 9,922 | | | 1,049 | | | 10,971 | | | |
R&D | 1,369 | | | (98) | | | 1,271 | | | |
SG&A | 5,502 | | | (24) | | | 5,478 | | | |
Other (income) expense, net | (287) | | | 57 | | | (230) | | | |
Earnings before taxes | 3,198 | | | 1,114 | | | 4,312 | | | |
Taxes on Earnings | 505 | | | 99 | | | 604 | | | |
Net Earnings | 2,693 | | | 1,015 | | | 3,708 | | | |
Diluted Earnings per Share | $ | 1.53 | | | $ | 0.58 | | | $ | 2.11 | | | |
Specified items reflect intangible amortization expense of $989 million and other net expenses of $125 million associated with restructuring actions, costs associated with acquisitions and other expenses. See page 20 for additional details regarding specified items.
A reconciliation of the second-quarter tax rates for 2024 and 2023 is shown below:
| | | | | | | | | | | | | | | | | | | | |
| 2Q24 | |
| ($ in millions) | Pre-Tax
Income | | Taxes on
Earnings | | Tax
Rate | |
| As reported (GAAP) | $ | 1,607 | | | $ | 305 | | | 19.0 | % | 1) |
| Specified items | 749 | | | 48 | | | | |
| Excluding specified items | $ | 2,356 | | | $ | 353 | | | 15.0 | % | |
| | | | | | | | | | | | | | | | | | | | |
| 2Q23 | |
| ($ in millions) | Pre-Tax
Income | | Taxes on
Earnings | | Tax
Rate | |
| As reported (GAAP) | $ | 1,636 | | | $ | 261 | | | 15.9 | % | 2) |
| Specified items | 566 | | | 48 | | | | |
| Excluding specified items | $ | 2,202 | | | $ | 309 | | | 14.0 | % | |
1)2024 Taxes on Earnings includes the recognition of approximately $25 million of net tax expense as a result of the resolution of various tax positions related to prior years.
2)2023 Taxes on Earnings includes the recognition of approximately $40 million of net tax expense as a result of the resolution of various tax positions related to prior years.
A reconciliation of the year-to-date tax rates for 2024 and 2023 is shown below:
| | | | | | | | | | | | | | | | | | | | |
| 1H24 | |
| ($ in millions) | Pre-Tax
Income | | Taxes on
Earnings | | Tax
Rate | |
| As reported (GAAP) | $ | 3,043 | | | $ | 516 | | | 17.0 | % | 3) |
| Specified items | 1,348 | | | 143 | | | | |
| Excluding specified items | $ | 4,391 | | | $ | 659 | | | 15.0 | % | |
| | | | | | | | | | | | | | | | | | | | |
| 1H23 | |
| ($ in millions) | Pre-Tax
Income | | Taxes on
Earnings | | Tax
Rate | |
| As reported (GAAP) | $ | 3,198 | | | $ | 505 | | | 15.8 | % | 4) |
| Specified items | 1,114 | | | 99 | | | | |
| Excluding specified items | $ | 4,312 | | | $ | 604 | | | 14.0 | % | |
3)2024 Taxes on Earnings includes the recognition of approximately $35 million of net tax expense as a result of the resolution of various tax positions related to prior years.
4)2023 Taxes on Earnings includes the recognition of approximately $62 million of net tax expense as a result of the resolution of various tax positions related to prior years.
Abbott Laboratories and Subsidiaries
Non-GAAP Revenue Reconciliation
Second Quarter and First Half Ended June 30, 2024 and 2023
($ in millions)
(unaudited)
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | 2Q24 | | 2Q23 | | % Change vs. 2Q23 |
| | | | | | | | | | | | | | Non-GAAP |
| | Abbott Reported | Impact of acquisition (a) | Impact from business exit (b) | Adjusted Revenue | | Abbott Reported | | Impact from business exit (b) | Adjusted Revenue | | Reported | | Adjusted | Organic |
| Total Company | | 10,377 | | (15) | | (8) | | 10,354 | | | 9,978 | | | (15) | | 9,963 | | | 4.0 | | | 3.9 | | 7.4 | |
| U.S. | | 3,934 | | (13) | | (8) | | 3,913 | | | 3,758 | | | (15) | | 3,743 | | | 4.7 | | | 4.6 | | 4.6 | |
| Intl | | 6,443 | | (2) | | — | | 6,441 | | | 6,220 | | | — | | 6,220 | | | 3.6 | | | 3.5 | | 9.2 | |
| | | | | | | | | | | | | | | |
| Total Nutrition | | 2,150 | | — | | (8) | | 2,142 | | | 2,076 | | | (15) | | 2,061 | | | 3.5 | | | 3.9 | | 7.5 | |
| U.S. | | 933 | | — | | (8) | | 925 | | | 881 | | | (15) | | 866 | | | 6.0 | | | 6.9 | | 6.9 | |
| Intl | | 1,217 | | — | | — | | 1,217 | | | 1,195 | | | — | | 1,195 | | | 1.7 | | | 1.7 | | 7.9 | |
| | | | | | | | | | | | | | | |
| Adult Nutrition | | 1,091 | | — | | (8) | | 1,083 | | | 1,052 | | | (15) | | 1,037 | | | 3.7 | | | 4.5 | | 9.9 | |
| U.S. | | 369 | | — | | (8) | | 361 | | | 374 | | | (15) | | 359 | | | (1.2) | | | 0.8 | | 0.8 | |
| Intl | | 722 | | — | | — | | 722 | | | 678 | | | — | | 678 | | | 6.4 | | | 6.4 | | 14.7 | |
| | | | | | | | | | | | | | | |
| Total Medical Devices | | 4,734 | | (15) | | — | | 4,719 | | | 4,295 | | | — | | 4,295 | | | 10.2 | | | 9.9 | | 12.1 | |
| U.S. | | 2,185 | | (13) | | — | | 2,172 | | | 1,913 | | | — | | 1,913 | | | 14.2 | | | 13.5 | | 13.5 | |
| Intl | | 2,549 | | (2) | | — | | 2,547 | | | 2,382 | | | — | | 2,382 | | | 7.0 | | | 7.0 | | 10.9 | |
| | | | | | | | | | | | | | | |
| Vascular | | 724 | | (15) | | — | | 709 | | | 715 | | | — | | 715 | | | 1.3 | | | (0.8) | | 1.2 | |
| U.S. | | 275 | | (13) | | — | | 262 | | | 264 | | | — | | 264 | | | 4.3 | | | (0.8) | | (0.8) | |
| Intl | | 449 | | (2) | | — | | 447 | | | 451 | | | — | | 451 | | | (0.4) | | | (0.6) | | 2.5 | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 1H24 | | 1H23 | | % Change vs. 1H23 |
| | | | | | | | | | | | Non-GAAP |
| Abbott Reported | Impact of acquisition (a) | Impact from business exit (b) | Adjusted Revenue | | Abbott Reported | | Impact from business exit (b) | Adjusted Revenue | | Reported | Adjusted | Organic |
| Total Company | 20,341 | | (57) | | (8) | | 20,276 | | | 19,725 | | | (15) | | 19,710 | | | 3.1 | | 2.9 | | 6.1 | |
| U.S. | 7,780 | | (53) | | (8) | | 7,719 | | | 7,686 | | | (15) | | 7,671 | | | 1.2 | | 0.6 | | 0.6 | |
| Intl | 12,561 | | (4) | | — | | 12,557 | | | 12,039 | | | — | | 12,039 | | | 4.3 | | 4.3 | | 9.6 | |
| | | | | | | | | | | | | |
| Total Nutrition | 4,218 | | — | | (8) | | 4,210 | | | 4,043 | | | (15) | | 4,028 | | | 4.3 | | 4.5 | | 7.6 | |
| U.S. | 1,811 | | — | | (8) | | 1,803 | | | 1,693 | | | (15) | | 1,678 | | | 7.0 | | 7.5 | | 7.5 | |
| Intl | 2,407 | | — | | — | | 2,407 | | | 2,350 | | | — | | 2,350 | | | 2.4 | | 2.4 | | 7.7 | |
| | | | | | | | | | | | | |
| Adult Nutrition | 2,150 | | — | | (8) | | 2,142 | | | 2,095 | | | (15) | | 2,080 | | | 2.6 | | 3.0 | | 7.6 | |
| U.S. | 733 | | — | | (8) | | 725 | | | 727 | | | (15) | | 712 | | | 0.8 | | 1.9 | | 1.9 | |
| Intl | 1,417 | | — | | — | | 1,417 | | | 1,368 | | | — | | 1,368 | | | 3.6 | | 3.6 | | 10.5 | |
| | | | | | | | | | | | | |
| Total Medical Devices | 9,187 | | (57) | | — | | 9,130 | | | 8,195 | | | — | | 8,195 | | | 12.1 | | 11.4 | | 13.1 | |
| U.S. | 4,219 | | (53) | | — | | 4,166 | | | 3,691 | | | — | | 3,691 | | | 14.3 | | 12.8 | | 12.8 | |
| Intl | 4,968 | | (4) | | — | | 4,964 | | | 4,504 | | | — | | 4,504 | | | 10.3 | | 10.2 | | 13.4 | |
| | | | | | | | | | | | | |
| Vascular | 1,413 | | (57) | | — | | 1,356 | | | 1,332 | | | — | | 1,332 | | | 6.1 | | 1.8 | | 3.3 | |
| U.S. | 529 | | (53) | | — | | 476 | | | 482 | | | — | | 482 | | | 9.8 | | (1.3) | | (1.3) | |
| Intl | 884 | | (4) | | — | | 880 | | | 850 | | | — | | 850 | | | 4.1 | | 3.6 | | 6.0 | |
(a) Abbott completed the acquisition of CSI on April 27, 2023. For purposes of calculating organic sales growth, the impact from this acquired business has been excluded from January through April 2024.
(b) Reflects the impact of discontinuing the ZonePerfect® product line in the Nutrition business. This action was initiated in March 2024.
Abbott Laboratories and Subsidiaries
Details of Specified Items
Second Quarter Ended June 30, 2024
(in millions, except per share data)
(unaudited)
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Acquisition or
Divestiture-
related (a) | | Restructuring
and Cost
Reduction
Initiatives (b) | | Intangible
Amortization | | Other (c) | | Total
Specifieds |
| Gross Margin | $ | 1 | | | $ | 32 | | | $ | 471 | | | $ | 2 | | | $ | 506 | |
| R&D | (1) | | | 1 | | | — | | | (41) | | | (41) | |
| SG&A | (11) | | | (10) | | | — | | | (36) | | | (57) | |
| Other (income) expense, net | (147) | | | — | | | — | | | 2 | | | (145) | |
| Earnings before taxes | $ | 160 | | | $ | 41 | | | $ | 471 | | | $ | 77 | | | 749 | |
| Taxes on Earnings (d) | | | | | | | | | 48 | |
| Net Earnings | | | | | | | | | $ | 701 | |
| Diluted Earnings per Share | | | | | | | | | $ | 0.40 | |
The table above provides additional details regarding the specified items described on page 13.
a)Includes the loss on the sale of a non-core business. Acquisition-related expenses include integration costs, which represent incremental costs directly related to integrating acquired businesses.
b)Restructuring and cost reduction initiative expenses include severance, outplacement and other direct costs associated with specific restructuring plans and cost reduction initiatives.
c)Other includes incremental costs to comply with the European Union's Medical Device Regulations (MDR) and In Vitro Diagnostics Medical Device Regulations (IVDR) requirements for previously approved products and an intangible asset impairment charge.
d)Reflects the net tax benefit associated with the specified items and tax expense as a result of the resolution of various tax positions related to prior years.
Abbott Laboratories and Subsidiaries
Details of Specified Items
Second Quarter Ended June 30, 2023
(in millions, except per share data)
(unaudited)
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Acquisition or
Divestiture-
related (a) | | Restructuring
and Cost
Reduction
Initiatives (b) | | Intangible
Amortization | | Other (c) | | Total
Specifieds |
| Gross Margin | $ | 7 | | | $ | 11 | | | $ | 498 | | | $ | 13 | | | $ | 529 | |
| R&D | (8) | | | 7 | | | — | | | (71) | | | (72) | |
| SG&A | (17) | | | (2) | | | — | | | (3) | | | (22) | |
| Other (income) expense, net | 47 | | | — | | | — | | | 10 | | | 57 | |
| Earnings before taxes | $ | (15) | | | $ | 6 | | | $ | 498 | | | $ | 77 | | | 566 | |
| Taxes on Earnings (d) | | | | | | | | | 48 | |
| Net Earnings | | | | | | | | | $ | 518 | |
| Diluted Earnings per Share | | | | | | | | | $ | 0.30 | |
The table above provides additional details regarding the specified items described on page 13.
a)Acquisition-related expenses include legal and other costs related to business acquisitions as well as integration costs, which represent incremental costs directly related to integrating acquired businesses. These costs were more than offset by fair value adjustments to contingent consideration related to business acquisitions.
b)Restructuring and cost reduction initiative expenses include severance, outplacement and other direct costs associated with specific restructuring plans and cost reduction initiatives.
c)Other includes incremental costs to comply with the European Union's Medical Device Regulations (MDR) and In Vitro Diagnostics Medical Device Regulations (IVDR) requirements for previously approved products and charges for intangible asset impairments.
d)Reflects the net tax benefit associated with the specified items and tax expense as a result of the resolution of various tax positions related to prior years.
Abbott Laboratories and Subsidiaries
Details of Specified Items
First Half Ended June 30, 2024
(in millions, except per share data)
(unaudited)
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Acquisition or
Divestiture-
related (a) | | Restructuring
and Cost
Reduction
Initiatives (b) | | Intangible
Amortization | | Other (c) | | Total
Specifieds |
| Gross Margin | $ | 2 | | | $ | 74 | | | $ | 943 | | | $ | 5 | | | $ | 1,024 | |
| R&D | (4) | | | (1) | | | — | | | (57) | | | (62) | |
| SG&A | (25) | | | (19) | | | — | | | (47) | | | (91) | |
| Other (income) expense, net | (135) | | | — | | | — | | | (36) | | | (171) | |
| Earnings before taxes | $ | 166 | | | $ | 94 | | | $ | 943 | | | $ | 145 | | | 1,348 | |
| Taxes on Earnings (d) | | | | | | | | | 143 | |
| Net Earnings | | | | | | | | | $ | 1,205 | |
| Diluted Earnings per Share | | | | | | | | | $ | 0.68 | |
The table above provides additional details regarding the specified items described on page 14.
a)Includes the loss on the sale of a non-core business. Acquisition-related expenses include integration costs, which represent incremental costs directly related to integrating acquired businesses, as well as other costs related to business acquisitions.
b)Restructuring and cost reduction initiative expenses include severance, outplacement and other direct costs associated with specific restructuring plans and cost reduction initiatives.
c)Other includes incremental costs to comply with the MDR and IVDR regulations for previously approved products and charges for investment and intangible asset impairments.
d)Reflects the net tax benefit associated with the specified items and tax expense as a result of the resolution of various tax positions related to prior years.
Abbott Laboratories and Subsidiaries
Details of Specified Items
First Half Ended June 30, 2023
(in millions, except per share data)
(unaudited)
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Acquisition or
Divestiture-
related (a) | | Restructuring
and Cost
Reduction
Initiatives (b) | | Intangible
Amortization | | Other (c) | | Total
Specifieds |
| Gross Margin | $ | 12 | | | $ | 32 | | | $ | 989 | | | $ | 16 | | | $ | 1,049 | |
| R&D | (12) | | | 8 | | | — | | | (94) | | | (98) | |
| SG&A | (21) | | | (6) | | | — | | | 3 | | | (24) | |
| Other (income) expense, net | 41 | | | — | | | — | | | 16 | | | 57 | |
| Earnings before taxes | $ | 4 | | | $ | 30 | | | $ | 989 | | | $ | 91 | | | 1,114 | |
| Taxes on Earnings (d) | | | | | | | | | 99 | |
| Net Earnings | | | | | | | | | $ | 1,015 | |
| Diluted Earnings per Share | | | | | | | | | $ | 0.58 | |
The table above provides additional details regarding the specified items described on page 14.
a)Acquisition-related expenses include legal and other costs related to business acquisitions as well as integration costs, which represent incremental costs directly related to integrating acquired businesses. These costs were partially offset by fair value adjustments to contingent consideration related to business acquisitions.
b)Restructuring and cost reduction initiative expenses include severance, outplacement and other direct costs associated with specific restructuring plans and cost reduction initiatives.
c)Other includes incremental costs to comply with the MDR and IVDR regulations for previously approved products and charges for intangible asset impairments.
d)Reflects the net tax benefit associated with the specified items and tax expense as a result of the resolution of various tax positions related to prior years.
v3.24.2
Cover
|
Jul. 18, 2024 |
| Document Information [Line Items] |
|
| Document Type |
8-K
|
| Document Period End Date |
Jul. 18, 2024
|
| Entity Registrant Name |
ABBOTT LABORATORIES
|
| Entity Incorporation, State or Country Code |
IL
|
| Entity File Number |
1-2189
|
| Entity Tax Identification Number |
36-0698440
|
| Entity Address, Address Line One |
100 Abbott Park Road
|
| Entity Address, City or Town |
Abbott Park
|
| Entity Address, State or Province |
IL
|
| Entity Address, Postal Zip Code |
60064-6400
|
| City Area Code |
224
|
| Local Phone Number |
667-6100
|
| Written Communications |
false
|
| Soliciting Material |
false
|
| Pre-commencement Tender Offer |
false
|
| Pre-commencement Issuer Tender Offer |
false
|
| Entity Emerging Growth Company |
false
|
| Entity Central Index Key |
0000001800
|
| Amendment Flag |
false
|
| NYSE CHICAGO, INC. |
|
| Document Information [Line Items] |
|
| Title of 12(b) Security |
Common Shares, Without Par Value
|
| Trading Symbol |
ABT
|
| Security Exchange Name |
CHX
|
| NEW YORK STOCK EXCHANGE, INC. |
|
| Document Information [Line Items] |
|
| Title of 12(b) Security |
Common Shares, Without Par Value
|
| Trading Symbol |
ABT
|
| Security Exchange Name |
NYSE
|
| X |
- DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission.
| Name: |
dei_AmendmentFlag |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
| Name: |
dei_DocumentPeriodEndDate |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:dateItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
| Name: |
dei_DocumentType |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:submissionTypeItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionAddress Line 1 such as Attn, Building Name, Street Name
| Name: |
dei_EntityAddressAddressLine1 |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- Definition
+ References
+ Details
| Name: |
dei_EntityAddressCityOrTown |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionCode for the postal or zip code
| Name: |
dei_EntityAddressPostalZipCode |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionName of the state or province.
| Name: |
dei_EntityAddressStateOrProvince |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:stateOrProvinceItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
| Name: |
dei_EntityCentralIndexKey |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:centralIndexKeyItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionIndicate if registrant meets the emerging growth company criteria. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
| Name: |
dei_EntityEmergingGrowthCompany |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
| Name: |
dei_EntityFileNumber |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:fileNumberItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionTwo-character EDGAR code representing the state or country of incorporation.
| Name: |
dei_EntityIncorporationStateCountryCode |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:edgarStateCountryItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
| Name: |
dei_EntityRegistrantName |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
| Name: |
dei_EntityTaxIdentificationNumber |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:employerIdItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionLocal phone number for entity.
| Name: |
dei_LocalPhoneNumber |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 13e
-Subsection 4c
| Name: |
dei_PreCommencementIssuerTenderOffer |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 14d
-Subsection 2b
| Name: |
dei_PreCommencementTenderOffer |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionTitle of a 12(b) registered security. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b
| Name: |
dei_Security12bTitle |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:securityTitleItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionName of the Exchange on which a security is registered. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection d1-1
| Name: |
dei_SecurityExchangeName |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:edgarExchangeCodeItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 14a
-Subsection 12
| Name: |
dei_SolicitingMaterial |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionTrading symbol of an instrument as listed on an exchange.
| Name: |
dei_TradingSymbol |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:tradingSymbolItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Securities Act
-Number 230
-Section 425
| Name: |
dei_WrittenCommunications |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- Details
| Name: |
dei_EntityListingsExchangeAxis=exch_XCHI |
| Namespace Prefix: |
|
| Data Type: |
na |
| Balance Type: |
|
| Period Type: |
|
|
| X |
- Details
| Name: |
dei_EntityListingsExchangeAxis=exch_XNYS |
| Namespace Prefix: |
|
| Data Type: |
na |
| Balance Type: |
|
| Period Type: |
|
|
Abbott Laboratories (NYSE:ABT)
Historical Stock Chart
From Aug 2024 to Sep 2024
Abbott Laboratories (NYSE:ABT)
Historical Stock Chart
From Sep 2023 to Sep 2024
